| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2005;111:38-43.)
© 2005 American Heart Association, Inc.
Coronary Heart Disease |
From the Department of Pediatrics, Mie University School of Medicine, Tsu, Mie (Y.M., H.S., Y.K.); the Department of Pediatrics, Yamada Red Cross Hospital, Watarai, Mie (H.H.); the Department of Pediatrics, Matsusaka City Hospital, Matsusaka, Mie (K.A., H.O.); the Department of Pediatrics, Tenri Hospital, Tenri, Nara (M.M.); the Department of Cardiology, Hyogo Childrens Hospital, Kobe, Hyogo (K.K.); the Department of Thoracic Cardiovascular Surgery, Mie University School of Medicine, Tsu, Mie (H.S.); and the Department of Community Nursing, Mie University School of Nursing, Tsu, Mie (M.N.), Japan.
Correspondence to Yoshihide Mitani, MD, PhD, Department of Pediatrics, Mie University School of Medicine, 2-174 Edobashi, Tsu City, Mie Prefecture, 514-8507, Japan. E-mail ymitani{at}clin.medic.mie-u.ac.jp
Received April 6, 2004; revision received September 28, 2004; accepted September 30, 2004.
| Abstract |
|---|
|
|
|---|
Methods and Results Cross-sectional study was performed to test the hypothesis that coronary sequelae are associated with elevated levels of inflammatory markers in patients late after KD (mean time interval after the onset, 10 years, 10 months). Levels of high-sensitivity C-reactive protein (CRP), serum amyloid-A (SAA), interleukin-6, and soluble intercellular adhesion molecule-1 were measured in the 4 groups (n=80): the referent group (n=15) and KD subgroups with normal coronary arteries from the onset (n=27); with regressed aneurysms (n=18); and with coronary artery lesions, such as persistent aneurysms, stenosis, and occlusion (n=20). CRP levels were significantly elevated in a KD subgroup with coronary artery lesions compared with the referent or other KD subgroups, as analyzed by ANOVA and ANCOVA after adjustment for a confounding factor body mass index. Levels of CRP, SAA, and interleukin-6 were positively correlated. Stepwise regression and logistic regression analyses support the association between the persistence of coronary artery lesions and the levels of CRP and SAA.
Conclusions Results demonstrate that the persistence of coronary lesions late after KD was independently associated with levels of CRP and SAA, suggesting that inflammation may be a novel functional aspect of coronary artery diseases late after KD.
Key Words: atherosclerosis coronary disease risk factors pediatrics prevention
| Introduction |
|---|
|
|
|---|
Functional aspects of vascular diseases late after KD have been reported only recently. Impairment in endothelial function was demonstrated in patients late after KD by quantitative coronary angiography using acetylcholine infusion or by ultrasound study of peripheral vessel responses to reactive hyperemia in recent reports, including ours.68 With the recent recognition that atherosclerosis is an inflammatory disease, as demonstrated in animal models and human,9 several inflammatory markers, especially high-sensitivity C-reactive protein (CRP) and serum amyloid-A (SAA), have recently been regarded as reliable clinical markers for the prediction of coronary events, independent of other known risk factors for coronary diseases.10 However, the association between coronary sequelae late after KD and levels of inflammatory markers for atherosclerosis is still unknown.
We therefore hypothesized that the persistence of coronary arterial lesions (CALs) late after KD is associated with elevated levels of inflammatory markers. We investigated the serum levels of CRP and SAA, as well as other inflammatory markers, in referents and patients with or without CALs late after KD. The association between the presence of CALs in KD patients and levels of inflammatory markers was analyzed by univariate and multivariate analyses.
| Methods |
|---|
|
|
|---|
3 mm in children younger than 5 years of age or
4 mm in children 5 years old or older, or if the diameter of the segment was
1.5 times that of the adjacent segment.11 The CALs in the long term were described according to standardized criteria.12 The study protocol was approved by the ethics committee of Mie University School of Medicine. The procedures followed were in accordance with institutional guidelines. Written informed consent was taken from each patient and/or his or her parents.
Study Subjects
Consecutive KD subjects meeting the following criteria were recruited from the outpatient clinics in Mie University Hospital, Matsusaka City Hospital, Tenri Hospital, and Hyogo Childrens Hospital between August 2002 and August 2003: (1) a diagnosis of KD; (2) echocardiographic evaluation of CALs in the acute phase of the illness and regular follow-up by use of echocardiography and/or coronary angiography, if indicated, until the time of the examination; and (3) the interval between the disease onset and the time of the investigation
5 years. Referent patients without a history of KD (n=15) included 10 age-matched consecutive patients with trivial congenital heart diseases and 5 age-matched consecutive patients with abnormal ECG findings in an outpatient clinic in Mie University hospital.
All the patients underwent detailed clinical examination for the assessment of general and cardiac conditions. Patient records were collected to evaluate the cardiac status. Exclusion criteria included infectious diseases and injury within 1 month before the study, chronic inflammatory disease, malignancy, ejection fraction <0.6, and clinical evidence of heart failure.
Laboratory Measurements
Venous blood samples were collected at the time of the clinical examination and stored at 80°C before analysis. CRP levels were measured in the serum by use of a commercially available high-sensitivity method (Dade Behring). SAA levels were measured with latex-enhanced immunoassay (Eiken Kagaku) that could detect concentrations as low as 2.6 µg/mL. Serum levels of interleukin-6 (IL-6) (Fuji Lebio) and soluble intercellular adhesion molecule-1 (sICAM-1) (R & D Systems) were measured by a high-sensitivity ELISA that allowed detection of levels as low as 0.3 pg/mL and 11 ng/ml, respectively. All measurements were performed in a single batch at the end of the study, and the laboratory staffs were blinded to the clinical data.
Statistical Analysis
All statistical analysis was performed with SPSS 11.0J for Windows (SPSS Inc). For the analysis of clinical characteristics, the significance of any difference in means among 3 or 4 groups was tested with a 1-way ANOVA, followed by a Scheffés F test; differences in proportions were tested with the
2 analysis. Because values of CRP, IL-6, and sICAM-1 have a skewed distribution, median concentrations were computed for these parameters, and the significance of any differences among the 4 groups was assessed by use of Kruskal Wallis test, followed by Mann-Whitney U test adjusted with a Bonferroni correction for multiple comparisons: adjusted probability values were reported after multiplying each probability value by 6. Logarithmically transformed values (natural logarithm) were also used, because the distribution of the residuals from the fitted models becomes normally distributed after logarithmic transformation. The values of logarithmically transformed values of CRP, IL-6, and sICAM-1 were used for the subsequent statistical analysis. Levels of these values among the 4 groups were evaluated by ANOVA, followed by Scheffés F test. After adjustment for body mass index, these values were compared by ANCOVA, in which a Bonferroni correction was applied for multiple comparison. Because levels of SAA were below the lowest detectable level in many patients, the proportions of patients above and below the lowest detectable level in patient groups were compared by
2 analysis. The correlation was analyzed with Pearson and/or Spearman correlation coefficients in KD patients. Partial correlations (adjusting for covariables: age, smoking, body mass index, family history of ischemic heart disease, systolic blood pressure, and total cholesterol/HDL cholesterol) for CRP, IL-6, and sICAM-1 were also calculated. To assess the relative strength of independent association of these values with clinical factors in KD patients, we used a stepwise multiple regression analysis (CRP, IL-6, and sICAM-1) and a logistic regression analysis (SAA). In stepwise regression analysis, we used log CRP, log IL-6, and log sICAM-1 values as dependent variables and evaluated the order of inclusion in the model of the following variables: age, smoking, body mass index, the presence of family history, systolic blood pressure, the total cholesterol/HDL cholesterol ratio, and coronary lesions. In a logistic regression analysis, we used similar variables to adjust for their potential effects on the SAA subgroups above or below 2.6 µg/mL. Data are reported as mean±SEM or median±interquartile range, and a value of P<0.05 was accepted as statistically significant.
| Results |
|---|
|
|
|---|
-globulin: 18 of 25 patients with normal coronary arteries from the acute illness, 17 of 18 patients with regressed aneurysms, and 13 of 19 patients with persistent CALs received
-globulin treatment during the acute illness. The detailed clinical characteristics of patients were described in the Table. All the 4 groups have similar characteristics with respect to height, body weight, body mass index, sex, the presence of family history of ischemic heart disease (one positive subject in a KD subgroup with normal coronary arteries; one in a KD subgroup with CALs), smoking (2 subjects only in a KD groups with normal coronary arteries), diabetes (none in any subgroups), age at the investigation, systolic and diastolic blood pressure, total cholesterol, HDL cholesterol, and the total cholesterol/HDL cholesterol ratio. Three KD subgroups have similar values with respect to age at the onset of KD and the time interval between the onset and the time of investigation.
|
Levels of CRP, SAA, IL-6, and sICAM-1
Levels of CRP were higher in KD patients with persistent CALs (median and interquartile ranges: 0.29, 0.19 to 0.38 mg/L) than in referents (0.09, 0.05 to 0.19 mg/L) (adjusted probability value, P=0.012), in KD patients with normal coronary arteries (0.13, 0.07 to 0.19 mg/L) (adjusted probability value=0.006) and in those with regressed aneurysms (0.11, 0.03 to 0.23 mg/L) (adjusted probability value, P=0.072), as analyzed by Kruskal-Wallis test, followed by Mann- Whitney U test adjusted with a Bonferroni correction for multiple comparisons (Figure 1A). Because 56 of 80 patients have levels of SAA below the lowest detectable level, the differences of the proportions of patients with levels
2.6 and <2.6 µg/mL among the 4 groups were analyzed by
2 analysis. The proportions of SAA
2.6 µg/mL were higher in KD patients with persistent CALs (
2.6/<2.6 µg/mL, 14/6) than those in referents (3/12) and in KD patients with normal coronary arteries (3/24) and with regressed aneurysms (4/14) (P=0.001). Levels of IL-6 were similar among the 4 groups, although IL-6 levels tend to be higher in KD patients with persistent CALs (0.90, 0.60 to 1.30 pg/mL) than in referents (0.70, 0.50 to 0.95 pg/mL) and in KD patients with normal coronary arteries (0.60, 0.50 to 1.00 pg/mL) and with regressed aneurysms (0.70, 0.50 to 0.90 pg/mL) (P=NS) (Figure 1A). There were no differences in sICAM-1 levels among the 4 groups.
|
Logarithmically transformed levels of CRP were significantly higher in KD patients with persistent CALs than in referents and in KD patients with normal coronary arteries and with regressed aneurysms, as analyzed by ANOVA (P<0.05) and by ANCOVA (P<0.05) after adjustment for body mass index (Figure 1, B and C). Logarithmically transformed levels of IL-6 were similar among the 4 groups, although IL-6 levels tend to be higher in KD patients with persistent CALs than in referents and in KD patients with normal coronary arteries and with regressed aneurysms, as analyzed by ANOVA and ANCOVA (P=NS) (Figure 1, B and C). There were no differences in logarithmically transformed levels of sICAM-1 among the 4 groups.
Correlation Between Levels of CRP, SAA, IL-6, and sICAM-1
In KD patients, logarithmically transformed levels of CRP were positively correlated with IL-6 (r=0.56, P<0.001) but not with sICAM-1, as analyzed by Pearsons correlation coefficients (Figure 2). After adjustment for confounding factors, levels of CRP were positively correlated with IL-6 (r=0.56, P<0.001) but not with sICAM-1, as analyzed by partial correlation coefficients.
|
In KD patients, levels of CRP were positively correlated with SAA (r=0.62, P<0.001) and IL-6 (r=0.52, P<0.001) but not with sICAM-1, as analyzed by Spearman correlation coefficients. Levels of SAA were positively correlated with IL-6 (r=0.44, P<0.001) but not with sICAM-1.
Factors Independently Associated With Levels of CRP, SAA, IL-6, and sICAM-1
To examine the independent predictors of logarithmically transformed levels of CRP, IL-6, and sICAM-1, we performed a stepwise regression analysis in KD patients. Among the clinical variables, the only predictor of levels of CRP was the presence of CALs (B=0.93±0.27, R=0.40, P=0.001). The predictor of levels of IL-6 was body mass index (B=0.06±0.02, R=0.32, P=0.01), not the presence of CALs. No factors were independent predictors of sICAM-1. To examine the independent predictors of SAA levels
the lowest detectable level in KD patients, we performed a logistic regression analysis. The presence of CALs was an independent predictor of positive SAA levels (OR=7.12; 95% CI, 1.82 to 27.77; P=0.005).
| Discussion |
|---|
|
|
|---|
The CRP and SAA levels in KD patients can be influenced by other factors related to CALs. Several recent reports in an apparently healthy population demonstrated that CRP levels are significantly associated with several cardiovascular risk factors: age, smoking, body mass index, and lipid-based risk factors.10 However, the confounding effects of these factors (ie, especially body mass index) on the association with KD are unlikely, because our study groups have similar characteristics with respect to coronary risk factors and because analyses by ANCOVA after adjustment for body mass index and by multivariate analysis further support the association. It seems to be unlikely that our results reflect ongoing subclinical ischemia or acute infection, which might have led to inadvertent elevations of both CRP and SAA. In this regard, the levels of CRP and SAA described in these data are substantially below those typically associated with the acute-phase response.13,14 Furthermore, elevations of CRP and SAA associated with acute myocardial infarction return to baseline within 8 to 10 days, whereas those associated with acute infection may return to the normal range within 2 to 3 weeks.13,14 Because blood samples in our study were obtained a minimum of 10 years after myocardial infarction and more than 4 weeks after the acute infection, inadvertent bias on this basis seems unlikely.
Levels of CRP may be affected by the difference in medication among study groups, because most of our KD patients with persistent CALs, but not those with normal coronary arteries or regressed aneurysms, took aspirin, dipyridamole, or ticlopidine. In fact, a recent study demonstrated that aspirin decreases CRP levels in adult patients with chronic stable angina,15 although this is still controversial.16 Therefore, it is possible that elevated CRP levels in the KD subgroup with CALs might rather have been underestimated, if anything, not overvalued, by such medication. The strong association between CALs after KD and levels of CRP and SAA is further supported by the present finding that the levels of CRP and SAA were positively correlated with those of IL-6. These findings were consistent with the mechanisms by which both CRP and SAA are produced in the liver in response to circulating cytokines, including IL-6.10,17 The reason why levels of IL-6 were not associated with the presence of CALs, whereas they were correlated with those of CRP and SAA, is unknown. IL-6 might be a less sensitive marker for some mechanisms related to CALs in KD patients, as is the case with acute coronary events in adult patients, in which CRP and SAA have higher predictive power of coronary events than IL-6 and sICAM-1.
Inflammatory responses observed in patients late after KD are consistent with previously documented endothelial dysfunction in such patients. Impaired endothelial function has been demonstrated in KD patients with CALs in previous studies.68 Because endothelium-derived nitric oxide (NO) inhibits the expression of adhesion molecules,18 decreased NO release may upregulate the expression of these molecules. In addition, because NO has antioxidant properties,18 the decreased NO production may unmask local inflammatory responses. Conversely, CRP directly reduces NO production by endothelial cells and increases endothelial expression of adhesion molecules.19 The exposure of endothelial cells to proinflammatory cytokines impairs endothelium-dependent vasorelaxation.20 In fact, in patients with ischemic heart diseases in adults, elevated CRP levels are associated with impaired endothelium-dependent relaxation.21 In KD patients, coronary endothelial function was impaired in patients with CALs but not in those with normal coronary arteries,7,8 although this is still controversial.6 Therefore, elevated CRP levels might be associated with endothelial dysfunction observed in KD patients in the long term.
Evidence indicative of inflammatory responses may offer a clue to the understanding of the mechanisms involved in acute coronary events in adults with a history of KD. Autopsy studies in these patients revealed persistent aneurysms with or without stenosis, which is associated with thrombosis.5 It is interesting to speculate that exaggerated procoagulant activity induced by exposure of endothelium to proinflammatory cytokines as well as by decreased NO production may lead to such thrombotic events.18 Alternatively, thrombus attached to coronary aneurysms and other lesions by the local rheological changes produced by an aneurysmal surface may activate inflammatory cascades via thrombin-mediated pathways: endothelial P-selectin and platelet-activating factor expression, and platelet-derived CD 40 ligand release, culminating in inducing inflammatory cytokines, including IL-6.22 These lines of evidence may suggest that inflammation may be a novel functional aspect of coronary artery diseases late after KD.
Elevated inflammatory markers may be associated with premature development of atherosclerosis in KD. Recent reports showed that inflammatory processes play a pivotal role in atherogenesis, which may account for initiation and progression of atherosclerosis.9,10 CRP is referred to as an acute-phase protein with multiple biological effects that may mediate several steps in the initiation and/or progression of atherosclerotic lesions.10 Recent data indicated that CRP levels add to the predictive value of standard measurements in determining the risk of the first myocardial infarction.23 In addition, coronary sequelae late after KD have been associated with an active remodeling process accompanied by expression of growth factors.24 Therefore, the present data are consistent with the hypothesis that the inflammatory process may be involved in the progression of CALs late after KD and coronary events in adolescents and young adults.
Limitations
Several limitations should be considered in interpreting our results. First, CRP levels were not elevated in KD patients with normal coronary arteries or regressed aneurysms in the present study. These findings suggest that inflammatory processes may not work in normal coronary arteries or regressed aneurysms in KD. However, the possibility that localized inflammation persists in coronary arteries in these mild cases cannot be excluded in the present study. Because Kawasaki vasculitis is heterogeneous in the systemic vasculature,25 most prominently in coronary arteries, low-grade and local inflammation may still remain undetected in these vessels. Second, our study design was cross-sectional. In this regard, the predictive value of CRP with respect to the coronary events in KD was not determined. Therefore, the present study warrants a cohort study. Third, the effects of the differences of the regimen of
-globulin therapy during the acute illness and antiplatelet agents in the long-term on inflammatory markers were undetermined in the present study because of the limitation of the number of the KD patients with persistent CALs.
Implications
The evidence of inflammatory responses, as well as of endothelial dysfunction, in patients late after KD is consistent with the hypothesis that a history of KD associated with persistent CALs may be a risk factor for atherosclerosis or coronary vascular events in adulthood, even in the absence of hypercholesterolemia. Because of the emerging interest in primary prevention of atherosclerotic cardiovascular diseases beginning in childhood,26 the history of KD associated with CALs could be considered in this regard.
A recent study showed that the potential effect of inflammation on coronary risk is attenuated by statin therapy in patients with relatively low cholesterol levels,27 suggesting the intriguing possibility that statin therapy may be useful for the prevention of future cardiovascular risks in KD patients via antiinflammatory mechanisms. Likewise, the use of aspirin at higher doses, ß-blockers, or ACE inhibitors might be considered for KD patients with respect to antiinflammatory mechanisms.2830 Similarly, avoidance of other risk factors, including smoking, obesity, and sedentary lifestyle, could be recommended for the appropriate KD patients.10
| References |
|---|
|
|
|---|
2. Yanagawa H, Yashiro M, Nakamura Y, et al. Nationwide surveillance of Kawasaki disease in Japan, 1984 to 1993. Pediatr Infect Dis J. 1995; 14: 6971.[Medline] [Order article via Infotrieve]
3. Taubert KA, Rowley AH, Shulman ST. Nationwide survey of Kawasaki disease and acute rheumatic fever. J Pediatr. 1991; 119: 279282.[CrossRef][Medline] [Order article via Infotrieve]
4. Suzuki A, Kamiya T, Arakaki Y, et al. Fate of coronary arterial aneurysms in Kawasaki disease. Am J Cardiol. 1994; 74: 822824.[CrossRef][Medline] [Order article via Infotrieve]
5. Burns JC, Shike H, Gordon JB, et al. Sequelae of Kawasaki disease in adolescents and young adults. J Am Coll Cardiol. 1996; 28: 253257.[Abstract]
6. Dhillon R, Clarkson P, Donald AE, et al. Endothelial dysfunction late after Kawasaki disease. Circulation. 1996; 94: 21032106.
7. Mitani Y, Okuda Y, Shimpo H, et al. Impaired endothelial function in epicardial coronary arteries after Kawasaki disease. Circulation. 1997; 96: 454461.[Medline] [Order article via Infotrieve]
8. Yamakawa R, Ishii M, Sugimura T, et al. Coronary endothelial dysfunction after Kawasaki disease: evaluation by intracoronary injection of acetylcholine. J Am Coll Cardiol. 1998; 31: 10741080.
9. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999; 340: 115126.
10. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res. 2001; 89: 763771.
11. Suzuki A, Kamiya T, Kuwahara N, et al. Coronary arterial lesions of Kawasaki disease: cardiac catheterization findings of 1100 cases. Pediatr Cardiol. 1986; 7: 39.[CrossRef][Medline] [Order article via Infotrieve]
12. Research Committee on Kawasaki disease. Report of the Subcommittee on Standardization of Diagnostic Criteria and Reporting of Coronary Artery Lesions in Kawasaki Disease. Tokyo, Japan: Ministry of Health and Welfare; 1983.
13. Berk BC, Weintraub WS, Alexander RW. Elevation of C-reactive protein in "active" coronary artery disease. Am J Cardiol. 1990; 65: 168172.[CrossRef][Medline] [Order article via Infotrieve]
14. Casl MT, Surina B, Glojnaric-Spasic I, et al. Serum amyloid A protein in patients with acute myocardial infarction. Ann Clin Biochem. 1995; 32 (pt 2): 196200.[Medline] [Order article via Infotrieve]
15. Ikonomidis I, Andreotti F, Economou E, et al. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation. 1999; 100: 793798.
16. Feldman M, Jialal I, Devaraj S, et al. Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay. J Am Coll Cardiol. 2001; 37: 20362041.
17. Kushner I. Regulation of the acute phase response by cytokines. Perspect Biol Med. 1993; 36: 611622.[Medline] [Order article via Infotrieve]
18. Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med. 1990; 323: 2736.[Medline] [Order article via Infotrieve]
19. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000; 102: 21652168.
20. Bhagat K, Moss R, Collier J, et al. Endothelial "stunning" following a brief exposure to endotoxin: a mechanism to link infection and infarction? Cardiovasc Res. 1996; 32: 822829.[CrossRef][Medline] [Order article via Infotrieve]
21. Fichtlscherer S, Rosenberger G, Walter DH, et al. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation. 2000; 102: 10001006.
22. Esmon CT. Inflammation and thrombosis. J Thromb Haemost. 2003; 1: 13431348.[CrossRef][Medline] [Order article via Infotrieve]
23. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002; 347: 15571565.
24. Suzuki A, Miyagawa-Tomita S, Komatsu K, et al. Active remodeling of the coronary arterial lesions in the late phase of Kawasaki disease: immunohistochemical study. Circulation. 2000; 101: 29352941.
25. Tanaka N, Sekimoto K, Naoe S. Kawasaki disease: relationship with infantile periarteritis nodosa. Arch Pathol Lab Med. 1976; 100: 8186.[Medline] [Order article via Infotrieve]
26. Kavey RE, Daniels SR, Lauer RM, et al. American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. Circulation. 2003; 107: 15621566.
27. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001; 344: 19591965.
28. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997; 336: 973979.
29. Beattie MS, Shlipak MG, Liu H, et al. C-reactive protein and ischemia in users and nonusers of ß-blockers and statins: data from the Heart and Soul Study. Circulation. 2003; 107: 245250.
30. Takeda T, Hoshida S, Nishino M, et al. Relationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive C-reactive protein levels. Atherosclerosis. 2003; 169: 155158.[CrossRef][Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
Y. Mitani, H. Ohashi, H. Sawada, Y. Ikeyama, H. Hayakawa, S. Takabayashi, K. Maruyama, H. Shimpo, and Y. Komada In Vivo Plaque Composition and Morphology in Coronary Artery Lesions in Adolescents and Young Adults Long After Kawasaki Disease: A Virtual Histology-Intravascular Ultrasound Study Circulation, June 2, 2009; 119(21): 2829 - 2836. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-T. Lin, S.-J. Chen, Y.-L. Ho, K.-C. Huang, C.-A. Chen, S.-N. Chiu, L.-C. Sun, W.-J. Lee, H.-C. Chen, J.-K. Wang, et al. Abnormal Matrix Remodeling in Adolescents and Young Adults with Kawasaki Disease Late after Onset Clin. Chem., November 1, 2008; 54(11): 1815 - 1822. [Abstract] [Full Text] [PDF] |
||||
![]() |
R.-E. W. Kavey, V. Allada, S. R. Daniels, L. L. Hayman, B. W. McCrindle, J. W. Newburger, R. S. Parekh, and J. Steinberger Cardiovascular Risk Reduction in High-Risk Pediatric Patients: A Scientific Statement From the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: Endorsed by the American Academy of Pediatrics Circulation, December 12, 2006; 114(24): 2710 - 2738. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Rosenkranz, D. J. Schulte, L. M.A. Agle, M. H. Wong, W. Zhang, L. Ivashkiv, T. M. Doherty, M. C. Fishbein, T. J.A. Lehman, K. S. Michelsen, et al. TLR2 and MyD88 Contribute to Lactobacillus casei Extract-Induced Focal Coronary Arteritis in a Mouse Model of Kawasaki Disease Circulation, November 8, 2005; 112(19): 2966 - 2973. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |